Prescription portability between countries posts 31–60

Agreed, and I will stop repeating the version of this I had been repeating.

This follows post #44 rather than contradicting it.

A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.

Somebody will have a better source than mine, and I hope they post it.

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

It is a small point and it changes the answer, which is an awkward combination.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

This has been discussed before and I could not find the thread, so, again.

On post #46 — agreed on the reasoning, with one qualification.

Customs practice varies between entry points within the same country, which is why two people in the same jurisdiction report different experiences honestly.

It is worth checking rather than assuming, which costs nothing.

The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.

Reading it again, the caveat matters more than the finding.

Picking up post #48: that is the part I would want checked first.

Prescription portability between countries: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.

The reason prescription portability between countries is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.

Comparing prices across countries without accounting for what is included — device, needles, dispensing — produces comparisons that are not comparisons.

The reasoning is more useful than the number, which is why I have shown it.

No disagreement from me. Posting only so the question does not look ignored.

Adding the measurement that post #52 says would settle it.

I would be cautious about generalising from the prescription portability between countries example above. It is a good example. It is one example.

Post #55 describes the usual case. This is about the unusual one.

A definition problem is doing most of the work in this prescription portability between countries discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.

Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.

Reciprocal recognition between regulators exists in some regions and not others, and assuming it is how people end up surprised.

This is the sort of thing that ought to be settled and apparently is not.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

I would not lead a decision with this, but I would not ignore it either.

Answering the question post #58 raises rather than the one it answers.

Reframing prescription portability between countries slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.